MYRX — Myrexis Income Statement
0.000.00%
HealthcareHighly SpeculativeMicro Cap
- $0.24m
- -$0.97m
Annual income statement for Myrexis, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2009 June 30th | 2010 June 30th | C2011 June 30th | 2012 June 30th | 2013 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Other Revenue | |||||
Total Revenue | 5.46 | 0.09 | 0.185 | 0 | 0 |
Cost of Revenue | |||||
Gross Profit | -49.2 | -28.1 | -22.1 | -11.6 | — |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 63.6 | 48.2 | 39.4 | 31.8 | 12 |
Operating Profit | -58.1 | -48.1 | -39.3 | -31.8 | -12 |
Gain / Loss on Sale of Assets | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -58.1 | -47 | -38.7 | -31.2 | -11.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | -58.1 | -47 | -38.7 | -31.2 | -11.6 |
Net Income Before Extraordinary Items | |||||
Net Income | -58.1 | -47 | -38.7 | -31.2 | -11.6 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -58.1 | -47 | -38.7 | -31.2 | -11.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.42 | -1.91 | -1.5 | -1.02 | -0.377 |
Dividends per Share |